SPCP31B10.04 Antibody

What is the SPCP31B10.04 protein and why is it relevant to fission yeast research?

SPCP31B10.04 is a protein found in Schizosaccharomyces pombe (fission yeast strain 972/ATCC 24843) with UniProt accession number Q9USH0. This protein is studied in the context of understanding fundamental cellular processes in fission yeast as a model organism. While limited information is available in the provided search results, researchers typically investigate such proteins to understand their role in signaling pathways, cell cycle regulation, or stress responses. Fission yeast serves as an excellent model organism due to its genetic tractability and conservation of many cellular processes with higher eukaryotes, making proteins like SPCP31B10.04 potentially relevant for understanding conserved mechanisms across species .

How should SPCP31B10.04 Antibody be stored and handled to maintain optimal activity?

For optimal maintenance of antibody activity, SPCP31B10.04 Antibody should be stored according to standard antibody protocols. Upon receipt, aliquot the antibody to avoid repeated freeze-thaw cycles that can degrade protein structure. Store the aliquots at -20°C for long-term storage or at 4°C for short-term use (typically 1-2 weeks). Before experimental use, thaw aliquots completely at room temperature and mix gently by inversion rather than vortexing to prevent protein denaturation. Some researchers report improved long-term stability by adding carrier proteins such as BSA (0.1-1%) to diluted antibody preparations. When using the antibody, maintain sterile technique and avoid contamination that might introduce proteases or other degradative enzymes that could compromise antibody function.

What are the recommended starting dilutions for different applications of the SPCP31B10.04 Antibody?

The optimal working dilution for SPCP31B10.04 Antibody varies based on the experimental application. As a general starting point, researchers should consider:

These ranges serve as initial guidelines, but researchers should perform titration experiments to determine the optimal concentration for their specific experimental conditions. Factors such as protein expression levels, cell type, and fixation methods can significantly impact the optimal antibody concentration required.

How can I validate the specificity of SPCP31B10.04 Antibody in my experimental system?

Validating antibody specificity is critical for ensuring reliable research findings. For SPCP31B10.04 Antibody, employ multiple complementary approaches:

First, perform Western blot analysis using wild-type S. pombe lysate alongside a knockout or knockdown strain lacking SPCP31B10.04, if available. The presence of a single band at the expected molecular weight in wild-type samples that is absent in knockout samples strongly supports antibody specificity. Second, conduct pre-absorption experiments by incubating the antibody with excess purified antigen before immunostaining or Western blotting, which should eliminate specific signals. Third, employ mass spectrometry analysis of immunoprecipitated material to confirm that the antibody is capturing the intended target protein. Finally, compare results with alternative antibodies targeting different epitopes of the same protein, if available. This multi-faceted approach provides robust validation of antibody specificity, which is essential for publication-quality research.

What are the optimal conditions for using SPCP31B10.04 Antibody in co-immunoprecipitation studies to investigate protein-protein interactions?

For successful co-immunoprecipitation (co-IP) with SPCP31B10.04 Antibody, careful optimization of experimental conditions is essential. Begin by selecting an appropriate lysis buffer that preserves protein-protein interactions; a good starting point is 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100, supplemented with protease inhibitors as referenced in fission yeast extraction protocols . Pre-clear cell lysates with protein A/G beads to reduce non-specific binding. For the immunoprecipitation, incubate 2-5 μg of SPCP31B10.04 Antibody with 500-1000 μg of total protein lysate overnight at 4°C, followed by addition of protein A/G beads for 2-4 hours.

Critical controls include a no-antibody condition, an isotype-matched control antibody, and if available, comparing results between wild-type and SPCP31B10.04-depleted cells. When analyzing co-IP results, use stringent washing conditions (at least 4-5 washes) to minimize non-specific interactions. For detection of weaker or transient interactions, consider using crosslinking reagents like DSP or formaldehyde before cell lysis. The sensitivity of the co-IP can be enhanced by using specialized magnetic beads conjugated with the antibody rather than loose protein A/G beads.

How can SPCP31B10.04 Antibody be adapted for studying protein localization during cell cycle progression in fission yeast?

To study SPCP31B10.04 protein localization across the cell cycle, implement a multi-dimensional approach combining immunofluorescence and live-cell imaging. For fixed-cell immunofluorescence, synchronize S. pombe cultures using standard methods such as nitrogen starvation or hydroxyurea block and release. Fix cells at defined time points using either 3.7% formaldehyde for 30 minutes or cold methanol for 8 minutes, and process for immunofluorescence using SPCP31B10.04 Antibody at 1:200 dilution. Co-stain with anti-tubulin antibody (such as TAT-1, as mentioned in the literature) to mark cell cycle stages .

For live-cell imaging, consider generating strains expressing fluorescently-tagged SPCP31B10.04 and validating the localization pattern using the antibody in fixed cells. To enhance signal detection, particularly for low-abundance proteins, implement signal amplification strategies such as tyramide signal amplification or use of secondary antibodies with brighter fluorophores. Quantitative analysis should include measurement of signal intensity, colocalization coefficients with organelle markers, and correlation with cell size/shape as indicators of cell cycle stage. This comprehensive approach allows for detailed characterization of dynamic changes in protein localization throughout the cell cycle.

What are common causes of high background when using SPCP31B10.04 Antibody, and how can these issues be resolved?

High background signal is a common challenge when working with antibodies in fission yeast. When using SPCP31B10.04 Antibody, several factors may contribute to elevated background:

Insufficient blocking: Extend blocking time to 2 hours at room temperature using 5% BSA or 5% normal serum from the species in which the secondary antibody was raised. Some researchers report success with fish gelatin as an alternative blocking agent for fission yeast samples. Excessive antibody concentration: Perform a dilution series to identify the optimal antibody concentration that maximizes specific signal while minimizing background. Non-specific binding to cell wall components: For immunofluorescence, ensure complete cell wall digestion using zymolyase or lysing enzymes before antibody incubation. Inadequate washing: Implement more stringent washing steps, such as increasing the number of washes (5-6 times) and the duration of each wash (10-15 minutes), and consider adding 0.1-0.3% Triton X-100 to washing buffers to reduce hydrophobic interactions.

Cross-reactivity with related proteins can also contribute to background. To address this, pre-absorb the antibody with cell lysate from a strain lacking the target protein, or use affinity-purified antibody fractions when available. Finally, consider the fixation method, as different proteins may require specific fixation protocols to maintain antigenicity while reducing non-specific binding.

How can I optimize antigen retrieval methods when using SPCP31B10.04 Antibody for immunohistochemistry of fission yeast cells?

Optimizing antigen retrieval for fission yeast immunohistochemistry requires careful consideration of the cellular context and protein properties. For SPCP31B10.04 Antibody, begin by evaluating different fixation methods, as these significantly impact epitope accessibility. Compare 4% paraformaldehyde (10-15 minutes at room temperature), cold methanol (6-10 minutes at -20°C), and a combination approach of mild paraformaldehyde fixation followed by methanol permeabilization.

For heat-induced epitope retrieval, prepare fixed cells in citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0) and heat to 95-98°C for 10-20 minutes, followed by slow cooling to room temperature. Alternatively, enzymatic retrieval using enzymes like proteinase K (1-5 μg/ml for 5-15 minutes) may be effective, especially for membrane-associated proteins. For each method, perform parallel experiments with varying intensities (time/temperature/concentration) to determine optimal conditions.

The cell wall presents a unique challenge in yeast. Pre-treatment with zymolyase (0.5-1 U/ml) or lysing enzymes from Trichoderma harzianum can significantly improve antibody penetration. For particularly challenging antigens, consider using detergent permeabilization with 0.1-0.5% Triton X-100 or saponin after fixation. Document all optimization steps methodically, as this information will be valuable for other researchers working with similar antibodies in fission yeast.

What considerations should be made when designing multiplexed immunofluorescence experiments that include SPCP31B10.04 Antibody?

Designing effective multiplexed immunofluorescence experiments with SPCP31B10.04 Antibody requires careful planning to avoid cross-reactivity and signal interference. First, determine the host species of the SPCP31B10.04 Antibody and select additional primary antibodies from different host species to enable the use of species-specific secondary antibodies. If using multiple antibodies from the same host species is unavoidable, consider sequential staining with complete blocking between rounds or employ directly conjugated primary antibodies.

Always include appropriate controls: single-antibody stains to verify specificity, secondary-only controls to assess non-specific binding, and when possible, samples lacking the target protein to confirm antibody specificity. For quantitative analysis, incorporate reference standards or calibration beads to normalize fluorescence intensity across experiments. This systematic approach ensures reliable data from multiplexed experiments, particularly important when studying protein complexes or signaling pathways in fission yeast.

How do I approach quantitative analysis of Western blot data using SPCP31B10.04 Antibody across different experimental conditions?

Quantitative analysis of Western blot data using SPCP31B10.04 Antibody requires rigorous methodology to ensure reproducible and statistically valid results. Begin by establishing a linear dynamic range for the antibody through a dilution series of your protein sample. This determines the protein concentration range where signal intensity is directly proportional to protein quantity. Include a loading control appropriate for your experimental conditions—α-tubulin (detected with antibodies like TAT-1) is commonly used in fission yeast studies .

For image acquisition, use a digital imaging system rather than film to ensure linear signal collection across a wide dynamic range. Capture images before signal saturation occurs, as saturated pixels will undermine quantification accuracy. For analysis, use software such as ImageJ with appropriate background subtraction. Normalize the target protein signal to your loading control for each lane, and then calculate relative expression compared to your control condition.

Statistical analysis should include at least three biological replicates. Apply appropriate statistical tests based on your experimental design—typically ANOVA followed by post-hoc tests for multiple comparisons. Report both the mean values and measures of dispersion (standard deviation or standard error). For experiments examining changes over time or across treatments, consider representing data as fold-change relative to baseline conditions, which often provides more interpretable results than absolute values.

What standards and controls should be implemented when validating phospho-specific or post-translational modification detection using SPCP31B10.04 Antibody?

Validating phospho-specific or post-translational modification (PTM) detection using SPCP31B10.04 Antibody requires comprehensive controls to ensure specificity and reliability. First, employ treatment controls: analyze samples treated with phosphatase inhibitors alongside samples treated with lambda phosphatase to demonstrate that the signal is genuinely phosphorylation-dependent. Similarly, for other PTMs, use inhibitors or enhancers of the specific modification (e.g., proteasome inhibitors for ubiquitination studies).

Genetic controls are equally important. When available, use mutant strains where the putative modification site has been altered (e.g., serine-to-alanine mutations for phosphorylation sites) to confirm antibody specificity. Stimulus response validation is also critical—demonstrate that the detected modification changes appropriately in response to relevant stimuli known to affect that modification (e.g., nitrogen starvation for many signaling pathways in fission yeast) .

For technical validation, include dot blot analysis with synthesized peptides containing the modified and unmodified forms of the epitope to confirm specificity. Mass spectrometry validation of immunoprecipitated protein provides the gold standard for confirming the presence and site of the modification. When reporting results, clearly document the evidence supporting the specificity of your modification detection, including all controls and their outcomes. This comprehensive validation approach is particularly important when studying novel modifications or when the antibody is being used to detect modifications for the first time.

How can I integrate data from SPCP31B10.04 Antibody-based techniques with other research methodologies to develop a comprehensive understanding of protein function?

Developing a comprehensive understanding of SPCP31B10.04 protein function requires integration of antibody-based data with complementary research methodologies. Begin with genetic approaches by analyzing phenotypes of deletion, overexpression, or point-mutation strains to establish functional relevance. Compare these phenotypes with the spatial and temporal expression patterns revealed by your antibody-based imaging to correlate localization with function. For example, if SPCP31B10.04 shows cell cycle-dependent localization changes, correlate this with cell cycle defects in mutant strains.

Integrate biochemical data by combining antibody-based protein detection with mass spectrometry to identify protein interaction partners and post-translational modifications. This can be particularly valuable when studying proteins involved in signaling pathways similar to the TSC pathway mentioned in the literature . For proteins involved in transcriptional regulation, complement antibody-based chromatin immunoprecipitation (ChIP) with RNA-seq or microarray analysis to connect protein binding sites with transcriptional outcomes.

Computational integration is equally important. Use bioinformatics tools to identify conserved domains and orthologous proteins across species, which can provide functional insights based on evolutionary conservation. Network analysis of protein-protein interactions can place your protein within a functional context and suggest additional hypotheses for testing. Finally, develop mathematical models that incorporate your experimental data to predict system behavior under various conditions, generating testable hypotheses for further experimentation. This multi-dimensional approach produces a more robust understanding of protein function than any single methodology alone.

What are the current limitations in researching SPCP31B10.04 and how might future antibody development address these challenges?

Current research on SPCP31B10.04 faces several limitations that impact experimental scope and data interpretation. First, the availability of validátion resources represents a significant challenge, as comprehensive knockout controls or competing antibodies targeting different epitopes may be limited for this specific fission yeast protein. This restricts researchers' ability to fully validate antibody specificity across different experimental conditions. Current antibody formulations may also have limited application versatility, potentially performing well in Western blotting but showing reduced efficacy in applications requiring native protein recognition, such as immunoprecipitation or ChIP.

Future antibody development could address these challenges through several approaches. The generation of monoclonal antibodies with defined epitope recognition would improve consistency across experimental batches and applications. Development of antibodies specifically validated for challenging applications like ChIP-seq would expand the research toolkit. Creating application-optimized formulations, such as directly conjugated antibodies for flow cytometry or super-resolution microscopy, would enable more sophisticated experimental designs. Additionally, developing antibodies against post-translationally modified forms of SPCP31B10.04 would facilitate studying dynamic regulation in response to various cellular stimuli.